Clinical trials of FDA-approved tirzepatide (Zepbound, Mounjaro) have shown average weight loss of 15-20% of body weight over 72 weeks when combined with lifestyle modifications-greater than semaglutide's 12-15% average
Since ROS induce tissue damage, thrombosis and red blood cell dysfunction that contribute to COVID-19 disease severity, administration of free radical scavengers could be beneficial for the most vulnerable patients (Laforge et al., 2020)
It also means someone with medical training has evaluated whether semaglutide is appropriate for you specifically, accounting for your medical history, medications, and individual risk factors
$78 Found the same product cheaper elsewhere
If your employer did include the benefit, you will need a prior authorization demonstrating BMI 30 or higher (or 27 with a comorbidity) and a documented lifestyle program, and you must show at least 5% weight loss to renew